OncoMatch/Clinical Trials/NCT05477264
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Is NCT05477264 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab for lymphoma.
Treatment: Tislelizumab — This clinical trial intends to analyze the efficacy of PD-1 inhibitor combined with radiotherapy for newly diagnosed NK/T-cell lymphoma. The investigational product in this clinical trial is tislelizumab, a PD-1 inhibitor. As a rationale for using PD-1 inhibitors in patients with NK/T-cell lymphoma, their efficacy has been proved several times mostly in patients with relapsed NK/T-cell lymphoma. Patients with low-stage NK/T-cell lymphoma usually receive high-concentration cytotoxic chemotherapy combined with radiotherapy, with treatment response rates of approximately 60 to 80%, but 80-90% of them experience hematological and non-hematologic toxicities during treatment. Therefore, this study intends to determine the efficacy and safety of PD-1 inhibitor(Tislelizumab) combined with radiotherapy as a first-line therapy compared with pre-existing cytotoxic chemotherapy combined with radiotherapy in patients with NK/T-cell lymphoma with low stage and International Prognostic Index.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IE, IIE
Excluded: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
No history of prior treatment
Cannot have received: radiotherapy
No history of prior treatment
Cannot have received: targeted therapy
No history of prior treatment
Lab requirements
Blood counts
Absolute neutrophil > 1,500/mm3; Hemoglobin > 9.0g/dL; Platelet > 75,000/mm3
Kidney function
Serum creatinine ≤ 2.0mg/dL
Liver function
Total bilirubin, AST/ALT < 3xULN
Cardiac function
LVEF < 50% as measured by echocardiography, QTc > 480msec (QTcF) on ECG at screening, unstable angina, ventricular arrhythmias except for benign PVC, medically uncontrolled supraventricular and nodal arrhythmias, conduction abnormality requiring a pacemaker, valve disease with documented cardiac dysfunction
Adequate bone marrow function, as defined by the following laboratory values... Adequate organ function, as defined by the following laboratory values... Cardiovascular exclusion criteria listed.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify